Table 1 Summary of AE reports submitted in FAERS.

From: Possible adverse events of imidazole antifungal drugs during treatment of vulvovaginal candidiasis: analysis of the FDA Adverse Event Reporting System

Baseline information

Total

Clotrimazole

Econazole

Ketoconazole

Miconazole

Number of AEs reports (n, %)

 Total

9985

2256 (22.59)

490 (4.91)

1901 (19.04)

5338 (53.46)

 0–18

206 (2.06)

36 (1.60)

0 (0)

15 (0.79)

155 (2.90)

 19–39

2169 (21.72)

392 (17.38)

50 (10.20)

288 (15.15)

1439 (26.96)

 40–59

2171 (21.74)

661 (29.30)

28 (5.71)

639 (33.61)

843 (15.79)

 ≥ 60

1948 (19.51)

464 (20.57)

286 (58.37)

483 (25.41)

715 (13.39)

 Abnormal or missing

3491 (34.96)

703 (31.16)

126 (25.71)

476 (25.04)

2186 (40.95)

Severity outcome (n, %)

 Total

3187 (31.92)

1407 (14.09)

365 (3.66)

675 (6.76)

740 (7.41)

 Death

546 (5.47)

339 (3.04)

109 (1.09)

53 (0.53)

45 (0.45)

 Disability

262 (2.62)

102 (1.02)

19 (0.19)

78 (0.78)

63 (0.63)

 Hospitalization

1852 (18.55)

756 (7.57)

205 (2.05)

391 (3.92)

500 (5.01)

 Life-threatening

527 (5.28)

210 (2.10)

32 (0.32)

153 (1.53)

132 (1.32)